Pharmaceutical Therapy for Osteoarthritis

PM and R

Volumn 4, Issue 5 SUPPL., 2012, Pages

  Cheng, David S ^a   Visco, Christopher J ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIULCER AGENT; CAPSAICIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOSAMINE CHONDROITIN; GLUCOSAMINE DERIVATIVE; IBUPROFEN; INDOMETACIN; LANSOPRAZOLE; MISOPROSTOL; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; ROFECOXIB; SULINDAC; TIAPROFENIC ACID; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB; WARFARIN;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; CEREBROVASCULAR DISEASE; CONSTIPATION; CONTACT DERMATITIS; CONTROLLED DRUG RELEASE; CORONARY ARTERY DISEASE; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DUODENUM ULCER; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HIP OSTEOARTHRITIS; HUMAN; HYPERTENSION; INFLAMMATION; JOINT DESTRUCTION; KNEE OSTEOARTHRITIS; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; NAUSEA; NEPHROTOXICITY; OSTEOARTHRITIS; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK FACTOR; RISK REDUCTION; SLEEP; STOMACH ULCER; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; NITRIC OXIDE; OSTEOARTHRITIS; PAIN; VASODILATOR AGENTS;

EID: 84861366755     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2012.02.009     Document Type: Article

References (68)

1. Cheng Y., Hootman J. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation: United States, 2007-2009. MMWR Morb Mortal Wkly Rep 2010, 59:1261-1265.
2. Lawrence R.C., Felson D.T., Helmick C.G., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
3. Dieppe P.A., Lohmander L.S. Pathogenesis and management of pain in osteoarthritis. Lancet 2005, 365:965-973.
4. Kidd B.L., Photiou A., Inglis J.J. The role of inflammatory mediators on nociception and pain in arthritis. Novartis Found Symp 2004, 260:122-133. discussion 133-138, 277-279.
5. Rabenda V., Manette C., Lemmens R., et al. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 2006, 33:1152-1158.
6. Buckwalter J.A., Saltzman C., Brown T. The impact of osteoarthritis: Implications for research. Clin Orthop Relat Res 2004, (427):S6-S15.
7. Björkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol Scand Suppl 1995, 103:1-44.
8. Brandt K.D., Mazzuca S.A., Buckwalter K.A. Acetaminophen, like conventional NSAIDs, may reduce synovitis in osteoarthritic knees. Rheumatology (Oxford) 2006, 45:1389-1394.
9. Lee C., Straus W.L., Balshaw R., et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: A meta-analysis. Arthritis Rheum 2004, 51:746-754.
10. Towheed T.E., Maxwell L., Judd M.G., et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006, (1). CD004257.
11. Herrero-Beaumont G., Ivorra J.A.R., Del Carmen Trabado M., et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007, 56:555-567.
12. Zhang W. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis?: A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004, 63:901-907.
13. Zimmerman H.J., Maddrey W.C. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure. Hepatology 1995, 22:767-773.
14. Whitcomb D.C., Block G.D. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994, 272:1845-1850.
15. Benson G.D., Koff R.S., Tolman K.G. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005, 12:133-141.
16. García Rodríguez L.A., Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001, 12:570-576.
17. Mort J.R., Shiyanbola O.O., Ndehi L.N., Xu Y., Stacy J.N. Opioid-paracetamol prescription patterns and liver dysfunction. Drug Saf 2011, 34:1079-1088.
18. New initiatives to help encourage appropriate use of acetaminophen McNeil Consumer Healthcare Division of McNEIL-PPC, Inc, Accessed January 31, 2012. http://www.tylenol.com/page2.jhtml?id=tylenol/news/newdosing.inc.
19. Lopes R.D., Horowitz J.D., Garcia D.A., Crowther M.A., Hylek E.M. Warfarin and acetaminophen interaction: A summary of the evidence and biologic plausibility. Blood 2011, 118:6269-6273.
20. Barrett B.J. Acetaminophen and adverse chronic renal outcomes: An appraisal of the epidemiologic evidence. Am J Kidney Dis 1996, 28(Suppl 1):S14-S19.
21. Forman J.P., Rimm E.B., Curhan G.C. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007, 167:394-399.
22. Pincus T., Koch G., Sokka T., et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001, 44:1587-1598.
23. Mastbergen S.C., Jansen N.W.D., Bijlsma J.W.J., Lafeber F.P.J.G. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: An in vitro study. Arthritis Res Ther 2006, 8:R2.
24. Ding C. Do NSAIDs affect the progression of osteoarthritis?. Inflammation 2002, 26:139-142.
25. Pincus T. Clinical evidence for osteoarthritis as an inflammatory disease. Curr Rheumatol Rep 2001, 3:524-534.
26. Smalley W.E., Griffin M.R. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. Gastroenterol Clin North Am 1996, 25:373-396.
27. Simon L.S., Hatoum H.T., Bittman R.M., Archambault W.T., Polisson R.P. Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA trial. Fam Med 1996, 28:204-210.
28. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000, 43:1905-1915. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.
29. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995, 123:241-249.
30. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002, (4). CD002296.
31. Johnson A.G. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging 1998, 12:17-27.
32. Schwartz J.I., Vandormael K., Malice M.P., et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002, 72:50-61.
33. Watson M.C., Brookes S.T., Kirwan J.R., Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev 2000, (2). CD000142.
34. Bradley J.D., Brandt K.D., Katz B.P., Kalasinski L.A., Ryan S.I. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991, 325:87-91.
35. Griffin M.R., Piper J.M., Daugherty J.R., Snowden M., Ray W.A. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991, 114:257-263.
36. Furst D.E. Are there differences among nonsteroidal antiinflammatory drugs?. Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994, 37:1-9.
37. Huskisson E.C., Berry H., Gishen P., Jubb R.W., Whitehead J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal Investigation of Nonsteroidal Anti inflammatory Drugs in Knee Osteoarthritis. J Rheumatol 1995, 22:1941-1946.
38. Hawkey C.J. COX-2 inhibitors. Lancet 1999, 353:307-314.
39. Bensen W.G., Fiechtner J.J., McMillen J.I., et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999, 74:1095-1105.
40. Mizuno H., Sakamoto C., Matsuda K., et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997, 112:387-397.
41. Simon L.S., Weaver A.L., Graham D.Y., et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999, 282:1921-1928.
42. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
43. Grainger R., Cicuttini F.M. Medical management of osteoarthritis of the knee and hip joints. Med J Aust 2004, 180:232-236.
44. Fitzgerald G.A. Coxibs and cardiovascular disease. N Engl J Med 2004, 351:1709-1711.
45. Zhang W., Nuki G., Moskowitz R.W., et al. OARSI recommendations for the management of hip and knee osteoarthritis: Part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
46. Chan F.K.L., Wong V.W.S., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet 2007, 369:1621-1626.
47. Latimer N., Lord J., Grant R.L., et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009, 339:2538.
48. Jordan K.M., Arden N.K., Doherty M., et al. EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
49. Beaulieu A.D., Peloso P.M., Haraoui B., et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: A randomized controlled trial. Pain Res Manage 2008, 13:103-110.
50. Kean W.F., Bouchard S., Roderich Gossen E. Women with pain due to osteoarthritis: The efficacy and safety of a once-daily formulation of tramadol. Pain Med 2009, 10:1001-1011.
51. Roth S.H. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998, 25:1358-1363.
52. Cepeda M.S., Camargo F., Zea C., Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006, (3). CD005522.
53. The management of chronic pain in older persons. American Geriatrics Society. J Am Geriatr Soc 1998, 46:635-651. AGS Panel on Chronic Pain in Older Persons.
54. Kjaersgaard-Andersen P., Nafei A., Skov O., et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip. A randomised, double-blind, multi-centre study. Pain 1990, 43:309-318.
55. Caldwell J.R., Hale M.E., Boyd R.E., et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999, 26:862-869.
56. McQuay H., Moore A., Justins D. Treating acute pain in hospital. BMJ 1997, 314:1531-1535.
57. Mason L., Moore R.A., Edwards J.E., et al. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. BMJ 2004, 328:995.
58. Heyneman C.A., Lawless-Liday C., Wall G.C. Oral versus topical NSAIDs in rheumatic diseases: A comparison. Drugs 2000, 60:555-574.
59. Lin J., Zhang W., Jones A., Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: Meta-analysis of randomised controlled trials. BMJ 2004, 329:324.
60. Evans J.M., McMahon A.D., McGilchrist M.M., et al. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: A record linkage case-control study. BMJ 1995, 311:22-26.
61. Williams A.C., Barry B.W. Penetration enhancers. Adv Drug Deliv Rev 2004, 56:603-618.
62. Tugwell P.S., Wells G.A., Shainhouse J.Z. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J Rheumatol 2004, 31:2002-2012.
63. Shainhouse J.Z., Grierson L.M., Naseer Z. A long-term, open-label study to confirm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther 2010, 17:566-576.
64. Mackenzie I.S., Rutherford D., MacDonald T.M., et al. Nitric oxide and cardiovascular effects: New insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res Ther 2008, 10(Suppl 2):S3.
65. Abramson S.B. Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 2008, 10(Suppl 2):S2.
66. Bendele A.M., Hulman J.F. Spontaneous cartilage degeneration in guinea pigs. Arthritis Rheum 1988, 31:561-565.
67. Bingham C.O., Buckland-Wright J.C., Garnero P., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.
68. Spector T.D., Conaghan P.G., Buckland-Wright J.C., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: Results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7:R625-R633.